PRISM BioLab is a biotechnology company focused on drug discovery using its proprietary PepMetics® Technology platform, which designs small molecules that mimic α-helix or β-turn peptides to target previously 'undruggable' proteins. The company operates two complementary business models: a proprietary development business (licensing out clinical candidates to pharma partners such as Eisai and Ohara Pharmaceutical) and a collaborative development business (co-creating programs with global pharmaceutical companies including Merck KGaA, Boehringer Ingelheim, Roche/Genentech, Eli Lilly, and Ono Pharmaceutical). Revenue is generated through upfront payments, collaborative research fees, development milestones, and post-commercialization royalties.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →PRISM BioLab is a biotechnology company focused on drug discovery using its proprietary PepMetics® Technology platform, which designs small molecules that mimic α-helix or β-turn peptides to target previously 'undruggable' proteins. The company operates two complementary business models: a proprietary development business (licensing out clinical candidates to pharma partners such as Eisai and Ohara Pharmaceutical) and a collaborative development business (co-creating programs with global pharmaceutical companies including Merck KGaA, Boehringer Ingelheim, Roche/Genentech, Eli Lilly, and Ono Pharmaceutical). Revenue is generated through upfront payments, collaborative research fees, development milestones, and post-commercialization royalties.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →